Last reviewed · How we verify
zidovudine+lamivudine+lopinavir/ritonavir
This combination inhibits HIV replication by blocking reverse transcriptase (zidovudine and lamivudine) and protease (lopinavir/ritonavir) enzymes required for viral reproduction.
This combination inhibits HIV replication by blocking reverse transcriptase (zidovudine and lamivudine) and protease (lopinavir/ritonavir) enzymes required for viral reproduction. Used for HIV-1 infection.
At a glance
| Generic name | zidovudine+lamivudine+lopinavir/ritonavir |
|---|---|
| Sponsor | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran |
| Drug class | Antiretroviral combination therapy (NRTI + PI) |
| Target | HIV reverse transcriptase and HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Zidovudine and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that prevent the virus from converting its RNA genome into DNA. Lopinavir/ritonavir is a protease inhibitor combination where ritonavir boosts lopinavir levels; together they block the protease enzyme needed to process viral proteins. This triple-drug regimen targets multiple steps in the HIV replication cycle.
Approved indications
- HIV-1 infection
Common side effects
- Nausea
- Diarrhea
- Headache
- Lipodystrophy
- Hyperglycemia
- Lactic acidosis
- Hepatotoxicity
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Early Infant HIV Treatment in Botswana (PHASE2, PHASE3)
- Research on the Psychological Status of Patients With HIV-1 Infection
- IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women (PHASE4)
- Antiretroviral Regime for Viral Eradication in Newborns (PHASE4)
- Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries (PHASE3)
- Preventing Sexual Transmission of HIV With Anti-HIV Drugs (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: